Right, they could have stopped the trial early due to futility and focus energy and limited resources elsewhere, e.g. developing their next generation plasmid construct with the p2a-linked design. They do appear to be confident right now in what they are observing.
Companies that don't have much faith in their advanced clinical program(s) tend to focus on their early development programs. None of that seems to be the case with Oncosec. In fact, it perturbs me that they haven't accelerated their next generation plasmid design or discuss it much, because I think its potential is enormous. But anyway, the bottom line is that they are behaving in a manner that shows a lot of confidence in IL-12 TAVO.
News 
Market Data 
Discover 
AI
